A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

N. Ruperto; P. Quartier; N.M. Wulffraat; P. Woo; A. Ravelli; R. Mouy; B. Bader-Meunier; S.J. Vastert; E. Noseda; D. D'Ambrosio; J. Lecot; A.B. Chakraborty; A. Martini; A. Chioato

doi:10.1002/art.33342

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

N. Ruperto
, P. Quartier
, N.M. Wulffraat
, P. Woo
, A. Ravelli
, R. Mouy
, B. Bader-Meunier
, S.J. Vastert
, E. Noseda
, D. D'Ambrosio
, J. Lecot
, A.B. Chakraborty
, A. Martini
, A. Chioato

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	557-67
Number of pages	11
Journal	Arthritis and Rheumatism
Volume	64
Issue number	2
DOIs	https://doi.org/10.1002/art.33342
Publication status	Published - 2012

Access to Document

10.1002/art.33342

http://onlinelibrary.wiley.com/doi/10.1002/art.33342/pdf

Cite this

Ruperto, N., Quartier, P., Wulffraat, N. M., Woo, P., Ravelli, A., Mouy, R., Bader-Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., Lecot, J., Chakraborty, A. B., Martini, A., & Chioato, A. (2012). A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 64(2), 557-67. https://doi.org/10.1002/art.33342

@article{99603da87de34f9da9a2728302ceb44c,

title = "A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features",

author = "N. Ruperto and P. Quartier and N.M. Wulffraat and P. Woo and A. Ravelli and R. Mouy and B. Bader-Meunier and S.J. Vastert and E. Noseda and D. D'Ambrosio and J. Lecot and A.B. Chakraborty and A. Martini and A. Chioato",

year = "2012",

doi = "10.1002/art.33342",

language = "English",

volume = "64",

pages = "557--67",

journal = "Arthritis and Rheumatism",

issn = "0004-3591",

publisher = "John Wiley \& Sons Inc.",

number = "2",

}

Ruperto, N, Quartier, P, Wulffraat, NM, Woo, P, Ravelli, A, Mouy, R, Bader-Meunier, B, Vastert, SJ, Noseda, E, D'Ambrosio, D, Lecot, J, Chakraborty, AB, Martini, A & Chioato, A 2012, 'A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features', Arthritis and Rheumatism, vol. 64, no. 2, pp. 557-67. https://doi.org/10.1002/art.33342

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. / Ruperto, N.; Quartier, P.; Wulffraat, N.M. et al.
In: Arthritis and Rheumatism, Vol. 64, No. 2, 2012, p. 557-67.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

AU - Ruperto, N.

AU - Quartier, P.

AU - Wulffraat, N.M.

AU - Woo, P.

AU - Ravelli, A.

AU - Mouy, R.

AU - Bader-Meunier, B.

AU - Vastert, S.J.

AU - Noseda, E.

AU - D'Ambrosio, D.

AU - Lecot, J.

AU - Chakraborty, A.B.

AU - Martini, A.

AU - Chioato, A.

PY - 2012

Y1 - 2012

U2 - 10.1002/art.33342

DO - 10.1002/art.33342

M3 - Article

C2 - 21953497

SN - 0004-3591

VL - 64

SP - 557

EP - 567

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

IS - 2

ER -